Carolyn eyeing merger with Axe

"A potential merger with axe will enable salix reps to achieve a previous unknown level of douchiness. The new axe body spray scent "temptation" combined with the FDA approval of Xifaxan for IBS will cause physicians to purchase large quantities of the drug just to get the rep out of the office. On the other hand salix reps will be able to cross sell axe products to drug stores across the country while logging fake calls from seedy strip mall parking lots." - Carolyn Logan, Wallstreet Journal

Carolyn eyeing merger with Axe